NEW YORK, February 7, 2017 /PRNewswire/ — Q BioMed, Inc. (OTCQB: QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.
The technology will utilize “uttroside B” and the compound's derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer was recently demonstrated in a November 3, 2016 study published in Scientific Reports, a Nature journal.
The compound has been isolated and characterized from the leaves of Solanum nigrum Linn, a plant widely used in traditional medicine. In the Scientific Reports study, researchers showed that in animal models, uttroside B was ten times more cytotoxic to the HepG2 liver cancer cell line than the only drug currently approved by the Food and Drug Administration for liver cancer.
Uttroside B drastically shrunk tumors in mice bearing human liver cancer xenografts. In addition, in pre-clinical experiments uttroside B induced cytotoxicity in all liver cancer cell lines, irrespective of their hepatitis B virus status, while being non-toxic to normal immortalized hepatocytes.
Chemotherapeutic options for liver cancer are limited, and the prognosis of patients remains challenging. According to the Centers for Disease Control and Prevention, it is the second most common cause of cancer deaths worldwide, claiming approximately 750,000 lives each year. In the US, the American Cancer Society estimates that 39,000 people will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.
The currently available drug has been shown to increase survival by only a short period of time. That drug also been reported to carry a variety of serious side effects, including increased blood pressure, bleeding problems, decreased blood flow to the heart and heart attacks.
In the Scientific Reports study, uttroside B was shown to be several times more potent than the currently available drug and did not cause noticeable side effects in vitro or in vivo.
“We are encouraged by the preclinical results we observed in this data and look forward to working with our collaborators at OMRF and RGCB to carry out further pre-clinical and clinical evaluation of uttroside B,” Q BioMed Inc. CEO Denis Corin said. “Our ultimate goal is to use it as an effective chemotherapeutic against liver cancer, which currently has very few therapeutic options.”
The uttroside B technology is covered by a provisional patent application. To see the full Scientific Reports study, go to: http://www.nature.com/articles/srep36318
About Q BioMed Inc.
Q BioMed Inc. (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus and cardiovascular disease.
RGCB is an autonomous national institution fully owned by the Government of India. It does pioneering research in cellular and molecular mechanisms of human animal and plant disease by amalgamating theory, modeling, simulation and experimental science.
Please visit our website http://www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Denis Corin, CEO
Q BioMed Inc.